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Dr Chukwumere Nwogu (Buffalo, NY). Dr Bousamra, I
congratulate you and your colleagues for this really intriguing
study and your excellent presentation.
With the anticipated marked increase in the number of small
lung nodules that we will probably need to evaluate as CT scan
screening for lung cancer gets really deployed in the community,
I think it is beneficial to have cost-effective tools to refine our man-
agement algorithms and to potentially avoid unnecessary or even
harmful procedures. I think this is very timely. I know it is early
in its development, but I find it very attractive. I also thank you
for providing the manuscript ahead of time.
I have 3 questions for you. In your estimation, what do you think
the estimated cost of this breath analysis would be for an individual
patient and how reproducible is it in various laboratories?
Dr Bousamra. The cost of doing the test right now is about $45.
There is the mass spectrometry charge, fee. The silicone wafers
cost a couple of dollars apiece. The chemical coating is very inex-
pensive. Then you would have to hire somebody to do the mass
spectrometry analysis if this was going to be a system-wide test.
I would estimate that the cost to an insurer would probably be
$200. We have not yet demonstrated reproducibility at other
institutions.
The next thing we want to do is enroll 2 or 3 times as many pa-
tients in the next year to confirm the results that we have already
have or to modify them. Quite frankly, when you begin something,
you are not quite as standardized as you should be because you are
figuring out how to do it. I think we could bemore quantitative than
we were to begin with about collecting breath. Why did we miss
some of those patients? I did not have time to say it, but of the
12 misses in early-stage disease, 10 of themwere adenocarcinoma.
So it may be that we are missing indolent tumors. They were small
adenocarcinomas, well differentiated for the most part. But it
may also be that the patients just did not give us a single
exhaled breath. It may be that they cheated and breathed a couple
of times, so that most of the breath in the bag was dead-space
ventilation.
Dr Nwogu. You suggested using this to assess a patient with
bulky disease and maybe decide not to perform a biopsy on such
a patient. In my mind, it is more attractive to evaluate small le-
sions, especially screen-detected lesions. You looked at 37 patients
who had stage 0 or stage I tumors that were less than 3 cm. You
quoted some values for the sensitivity of your breath analysis1080 The Journal of Thoracic and Cardiovascular Surversus PET scan, but in that particular subset of patients, what
was the specificity of the analysis?
Dr Bousamra. Well, the specificity is the same. It is still
dependent on the number of carbonyls that you choose to be pos-
itive. If we define 2 or more carbonyl compounds as being pos-
itive, for those small lesions we have a sensitivity of 73% and a
specificity of about 80%. In my thinking on helping to avoid
intervention in benign diseases, I agree with you, it is not the pri-
mary problem. The big factor is that we have got to study or see
how we do with 1-cm, 1.5-cm, 0.7-cm lesions that are detected
on a screening CT scan. That is the elephant in the room. But,
oh, by the way, the test never misses bigger tumors, at least in
our experience. If the tumor was bigger than 3 cm, breath anal-
ysis was never wrong. Say a patient has a 3-cm hilar lesion and
you think it is histoplasmosis, but it is active on PET and every-
body is worried to death about it, but if the patient blows a stone-
cold negative breath analysis, it really probably is negative, and
that can be reassuring. You are not going to perform a biopsy on
it 3 or 4 times. I am not saying that I am going to do that
tomorrow, but maybe if the data are confirmed in a larger study,
it could be helpful and reassuring to the patient and to the
clinician.
Dr Nwogu. Have you considered combining the findings from
the PETand your breath analysis? For instance, if you combine the
2 studies, the 2 tests, on a single patient, would you be able to in-
crease the sensitivity and specificity even further?
Dr Bousamra.No. We looked at that, and it did not really work
out that way. I threw out a slide that looked at the benign patients
and where they were false-negative and false-positive. They
migrate together to a fair extent. I do not have enough benign pa-
tients to really answer that confidently, but so far they have not
been helpful in combination.
Dr Akif Turna (Istanbul, Turkey). Did you look at the diabetes
status of the patients and the consumption of alcohol in these 2
groups, especially 3 to 5 hours before the test, and the glucose level
of the patients? That may affect the ketone bodies and the alde-
hydes in the blood.
Dr Bousamra. We did record what their diet was. Most of the
tests were taken early in the morning, so I hope they were not
drinking too much in the few hours before. We did not specifically
record alcohol intake. The point about these compounds is that
they are very specific to cancer. We do not find alcohol-related
compounds in increased concentrations. The glucose in the dia-
betics, they had higher levels of acetate, but not the carbonyls
we were interested in.
Dr Daniel Miller (Marietta, Ga). Excellent presentation.
I have 2 questions. Was there a difference with regard to histol-
ogy -adenocarcinoma versus squamous? The second question, for
your healthy baseline individuals, did you study any patients with
head and neck cancer? I think this would be important because of
the relationship between aerodigestive cancers and smoking; your
test could be positive for a head and neck cancer that was unde-
tected instead of a lung cancer.
Dr Bousamra. To answer the second question, yes, we have a
few head and neck cancers that I did not present and they were pos-
itive. We also have a variety of other cancers that are metastatic to
the lung that were positive on exhaled breath.
What was the first question?gery c September 2014
Bousamra et al Evolving Technology/Basic ScienceDrMiller.Was there a difference between adenocarcinoma and
squamous?
Dr Bousamra. There is a cancer marker profile that is specific
for small cell lung cancer. Pentanone and n-pentanal are more
diagnostic of small cell tumors. But I do not know whether that
is a tumor volume relationship. Also, 2-butanone is higher for
stages beyond stage I, as we noticed a difference between those
2. We did not find any strong correlation differentiating between
adenocarcinoma and squamous cell carcinoma.The Journal of Thoracic and CarDr Miller. Can you do this test with urine?
Dr Bousamra. Well, Linus Pauling did.
DrMiller. Smell it, sniff it? Bring a dog in here and wewill let it
smell your urine. (Laughter.)
Dr Bousamra. It is a good question.
DrMiller. But you cannot fake a urine test. Well, some athletes
can, but most of the time a patient will not fake a urine test.
Dr Bousamra. It is a good question and we should look at
whether a combined analysis would be beneficial.diovascular Surgery c Volume 148, Number 3 1081
E
T
/B
S
